Last reviewed · How we verify
Vfend - voriconazole
Vfend - voriconazole is a Azole antifungal Small molecule drug developed by Pfizer. It is currently in Phase 3 development for Treatment of invasive aspergillosis, candidemia, and other serious fungal infections. Also known as: Vfend.
Voriconazole is an antifungal medication that works by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes.
Voriconazole, also known as Vfend, is a small molecule inhibitor that targets the cytochrome P450 51 enzyme, specifically inhibiting lanosterol 14-alpha demethylase. It is used to treat various conditions, including coronavirus infection (COVID-19), according to ClinicalTrials.gov.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Anti-infectives pathway favourability
+2.0pp
Microbiological endpoints + non-inferiority designs raise approval rates above baseline. -
Big-pharma sponsor
+3.0pp
Pfizer is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Vfend - voriconazole |
|---|---|
| Also known as | Vfend |
| Sponsor | Pfizer |
| Drug class | Azole antifungal |
| Target | Lanosterol 14α-demethylase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
It achieves this by targeting the enzyme lanosterol 14α-demethylase, which is necessary for the conversion of lanosterol to ergosterol. This disruption of ergosterol synthesis ultimately leads to the death of fungal cells. Voriconazole has a broad spectrum of activity, making it effective against a wide range of fungal pathogens.
Approved indications
- Treatment of invasive aspergillosis, candidemia, and other serious fungal infections
Common side effects
- Headache
- Nausea
- Vomiting
- Abdominal pain
- Diarrhea
Key clinical trials
- A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity (PHASE1)
- A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) (PHASE1, PHASE2)
- A Multicenter RCT of "3+7" vs Venetoclax + CACAG in Newly Diagnosed Mid/High-Risk AML Patients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Study on the Drug Interaction Between Buagafuran and Voriconazole (PHASE1)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vfend - voriconazole CI brief — competitive landscape report
- Vfend - voriconazole updates RSS · CI watch RSS
- Pfizer portfolio CI
Frequently asked questions about Vfend - voriconazole
What is Vfend - voriconazole?
How does Vfend - voriconazole work?
What is Vfend - voriconazole used for?
Who makes Vfend - voriconazole?
Is Vfend - voriconazole also known as anything else?
What drug class is Vfend - voriconazole in?
What development phase is Vfend - voriconazole in?
What are the side effects of Vfend - voriconazole?
What does Vfend - voriconazole target?
Related
- Drug class: All Azole antifungal drugs
- Target: All drugs targeting Lanosterol 14α-demethylase
- Manufacturer: Pfizer — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of invasive aspergillosis, candidemia, and other serious fungal infections
- Also known as: Vfend
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing